These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 39304893)

  • 21. Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients.
    Kim SH; Jo MW; Kim HJ; Ahn JH
    Health Qual Life Outcomes; 2012 Dec; 10():151. PubMed ID: 23244763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimating a Minimal Important Difference for the EQ-5D-5L Utility Index in Dialysis Patients.
    Siriwardana AN; Hoffman AT; Morton RL; Smyth B; Brown MA
    Value Health; 2024 Apr; 27(4):469-477. PubMed ID: 38307389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Indirect and Direct Mapping of the Cancer-Specific EORTC QLQ-C30 onto EQ-5D-5L Utility Scores.
    Meunier A; Soare A; Chevrou-Severac H; Myren KJ; Murata T; Longworth L
    Appl Health Econ Health Policy; 2022 Jan; 20(1):119-131. PubMed ID: 34554442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after.
    Miret C; Orive M; Sala M; García-Gutiérrez S; Sarasqueta C; Legarreta MJ; Redondo M; Rivero A; Castells X; Quintana JM; Garin O; Ferrer M;
    Qual Life Res; 2023 Apr; 32(4):989-1003. PubMed ID: 36630024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
    Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
    Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases.
    Raman S; Ding K; Chow E; Meyer RM; van der Linden YM; Roos D; Hartsell WF; Hoskin P; Wu JSY; Nabid A; Haas R; Wiggenraad R; Babington S; Demas WF; Wilson CF; Wong RKS; Zhu L; Brundage M
    Qual Life Res; 2018 Apr; 27(4):1089-1098. PubMed ID: 29188483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing the validity of EQ-5D-5L in people with head & neck cancer: Does a generic quality of life measure perform as well as a disease-specific measure in a patient population?
    Davies A; Waylen A; Leary S; Thomas S; Pring M; Janssen B; Beynon R; Lang S; Schimansky S; Hurley K; Ness A
    Oral Oncol; 2020 Feb; 101():104504. PubMed ID: 31835074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Minimal important differences in the EORTC QLQ-C30 in patients with advanced cancer.
    Bedard G; Zeng L; Zhang L; Lauzon N; Holden L; Tsao M; Danjoux C; Barnes E; Sahgal A; Poon M; Chow E
    Asia Pac J Clin Oncol; 2014 Jun; 10(2):109-17. PubMed ID: 23551530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients.
    Khan I; Morris S; Pashayan N; Matata B; Bashir Z; Maguirre J
    Health Qual Life Outcomes; 2016 Apr; 14():60. PubMed ID: 27072351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30.
    van Dongen-Leunis A; Redekop WK; Uyl-de Groot CA
    Value Health; 2016; 19(6):834-843. PubMed ID: 27712712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
    Proskorovsky I; Lewis P; Williams CD; Jordan K; Kyriakou C; Ishak J; Davies FE
    Health Qual Life Outcomes; 2014 Mar; 12():35. PubMed ID: 24618388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
    Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
    Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Establishing anchor-based minimally important differences (MID) with the EORTC quality-of-life measures: a meta-analysis protocol.
    Musoro ZJ; Hamel JF; Ediebah DE; Cocks K; King MT; Groenvold M; Sprangers MAG; Brandberg Y; Velikova G; Maringwa J; Flechtner HH; Bottomley A; Coens C;
    BMJ Open; 2018 Jan; 8(1):e019117. PubMed ID: 29326191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic review reveals that EQ-5D minimally important differences vary with treatment type and may decrease with increasing baseline score.
    Cheng LJ; Chen LA; Cheng JY; Herdman M; Luo N
    J Clin Epidemiol; 2024 Oct; 174():111487. PubMed ID: 39084578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mapping the EORTC QLQ-C30 onto the EQ-5D-5L index for patients with paroxysmal nocturnal hemoglobinuria in France.
    Wojciechowski P; Wdowiak M; Hakimi Z; Wilson K; Fishman J; Nazir J; Toumi M
    J Comp Eff Res; 2023 May; 12(5):e220178. PubMed ID: 37052120
    [No Abstract]   [Full Text] [Related]  

  • 36. Minimally Important Difference of the EQ-5D-5L Index Score in Adults with Type 2 Diabetes.
    McClure NS; Sayah FA; Ohinmaa A; Johnson JA
    Value Health; 2018 Sep; 21(9):1090-1097. PubMed ID: 30224114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma.
    Reni M; Braverman J; Hendifar A; Li CP; Macarulla T; Oh DY; Riess H; Tempero M; Lu B; Marcus J; Joshi N; Botteman M; Dueck AC
    Ann Surg Oncol; 2021 Nov; 28(12):7545-7554. PubMed ID: 33813673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
    Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
    Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
    Fehm T; Cottone F; Dunton K; André F; Krop I; Park YH; De Laurentiis M; Miyoshi Y; Armstrong A; Borrego MR; Yerushalmi R; Duhoux FP; Takano T; Lu W; Egorov A; Kim SB
    Lancet Oncol; 2024 May; 25(5):614-625. PubMed ID: 38697155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials.
    Maringwa JT; Quinten C; King M; Ringash J; Osoba D; Coens C; Martinelli F; Vercauteren J; Cleeland CS; Flechtner H; Gotay C; Greimel E; Taphoorn MJ; Reeve BB; Koch JS; Weis J; Smit EF; van Meerbeeck JP; Bottomley A;
    Support Care Cancer; 2011 Nov; 19(11):1753-60. PubMed ID: 20886240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.